Optimize your mRNA production by identifying an optimum set of conditions for the IVT reaction that produces high-quality mRNA in high yield using a design of experiment (DoE) approach.

Explore guidelines for the use of SP6 RNA Polymerase in mRNA synthesis and your mRNA production processes.

Learn about the problem of immunogenicity of mRNA, modified mRNA via in vitro transcription production, and choosing fit-for-purpose modified ribonucleotides.

Learn about tools to optimize the IVT reaction for enhanced mRNA yield, along with how factors such as magnesium ion and nucleotide concentrations significantly impact that IVT reaction performance.

Explore the advantages of mRNA technology, the process steps of large-scale mRNA production, and the effect of common contaminants on mRNA manufacturing.

Learn what some practical considerations are for implementing NAT-based methods, where concrete recommendations are necessary, and how guidelines can remain relevant for new medicinal products.

Learn about a solution for streamlining workflow in novel biologics while collecting quality data, by combining single-use microbioreactors with advanced automation and analytical platforms.

In this assessment of the in vitro glycoengineering technology we determine if it is suitable for the development, manufacturing, and analysis of therapeutic proteins.

Expert panelists provide commentary on specific steps considered to be challenging in mRNA therapeutic development as well as new technologies in mRNA therapeutic development.

Novel excipients or active substances? In this segment of Risk Reduction In mRNA Therapeutic Development, we address the debate and discuss LNP-related inflammatory response concerns.

What challenges do you consider the most formidable in your own mRNA therapeutic development environments?

Learn more about LNP complexity, fragility, and other lipid nanoparticle considerations in this segment from the Bioprocess Online Live digital event Risk Reduction In mRNA Therapeutic Development.

Safety of mRNA vaccines and therapeutics is paramount to approval, but process dependent. Listen to this discussion which addresses safety risks and how mRNA developers are tackling the challenges.

In this segment from the Bioprocess Online Live digital event Risk Reduction In mRNA Therapeutic Development, hundreds of audience members tell us what forms of vaccine and therapeutics they’re developing.

Listen in on a discussion surrounding questions about chromatography and column-free processes in the development of mRNA vaccines and therapeutics.

Listen in on a discussion reviewing key drivers behind the flurry of activity in mRNA therapeutic development and begin to address the rate-limiting risks to mRNA therapeutic development.

Learn about a family of instruments that performs precise measurements and enables informed decisions and fast time response.

Learn more about how certain glycoforms can be enriched in downstream processing using discrete enzymatic reactions with clear kinetics and predictable outcomes.

Learn more about CustomBiotech and what they can provide to meet your mRNA needs.